

BIOLIFE REMEDIES INC.

INFORMATION AND DISCLOSURE STATEMENT
PURSUANT TO RULE 15c2-(11)(a)(5)

All information contained in this Information and Disclosure Statement has been compiled to fulfill the disclosure requirements of Rule 15c2-11 (a)(5) promulgated under the Securities Exchange Act of 1934, as amended. The enumerated captions contained herein correspond to the sequential format as set forth in the rule.

Item (i): The exact name of the issuer and its predecessor (if any).

BIOLIFE REMEDIES INC., (hereinafter referred to as the "Company" or "BIOLIFE"), formerly known as Emerson Oil & Gas Inc.

Item (ii): The address of its principle executive offices.

BioLife Remedies Inc.
The RBC- Royal Bank Building
Suite 501 - 675 W. Hastings Street
Vancouver, BC
V6B 1N2
Email: info@blfrproducts.com
Tel: 604-630-8881
Fax:604-630-8877
Toll Free: 1-866-630-8881

Item (iii): The state and date of incorporation.

The issuer was organized by the filing of the Articles of Incorporation with the Secretary of State Nevada on April 12, 2004. The Company changed its name to BioLife Remedies Inc. through the filing of merger documents with the state of Nevada on January 18, 2007.

Item (iv): The exact title and class of each class of securities outstanding.

Security Symbol:	BLRS
CUSIP Number:	09063B100
Common Stock:	500,000,000 authorized
Preferred Stock:	none authorized

Item (v): The par or stated value of the security.

One Hundred Fifty Million (500,000,000) shares of Common Stock with \$0.0001 par value.

Item (vi): The number of shares or total amount of the securities outstanding and a list of securities offerings in the past two years.

A.

- (i) Number of shares outstanding as at March 15, 2007
- (ii) There are 500,000,000 shares of Common Stock with \$0.0001 par value authorized. There is no preferred stock authorized.
- (iii) There are approximately 32,000,000 shares issued and outstanding.
- (iv) There are approximately 10,000,000 shares in the public float.
- (v) The Company has approximately Five Hundred and Thirty (530) shareholders.
- (vi) There are no preferred shares outstanding. The Company has issued no authorized preferred shares.

No shares were issued for services.

Item (vii): The name and address of the transfer agent.

Continental Stock Transfer
17 Battery Place
New York, NY 10004

Continental Stock Transfer is registered under the Exchange Act and is an SEC approved transfer agent.

Item (viii): The nature of the issuer's business.

BIOLIFE REMEDIES, INC. (BLRS) combines Traditional Chinese Medicine (TCM), Western academic research and development practices with the newest scientific technology to produce effective medical and health-care products to combat serious diseases. TCM is a natural medical framework developed 3000 years ago in China and over the centuries countless medical formulas have been developed to treat the most common diseases known to afflict man.

For generations the BioLife Group has engaged in TCM as a profession developing 108 master medical formulas. In the Nineties under the leadership of Mr. Jack Guo, BLRS was formed by a group of rhizotomists, herbologists, pharmacists, and TCM practitioners to develop effective natural herbal supplements based on BLRS's master formulas. Over the years 11 products were successfully developed by BFLR to treat various diseases including; diabetes, prostatitis, osteoporosis, cerebrovascular disease, cardiac vascular disease, hypertension, menopausal syndrome, male sexual disorder, female sexual disorder, and intelligence development in children.

Presently the company is concentrating on Natural Supplements to combat the world's most expensive and debilitating disease—DIABETES. Zutro™, Betatro™, Dia-Kids™ and Di-Agra™ address a well-defined and unanswered need in diabetic medication: a natural medical product that not only treats Diabetes but its many complications.

Quality Control

All of our raw materials must pass strict quality controls before they are consumed. All BioLife Group supplements are manufactured using Good Manufacturing Practices (GMP Standards). In addition, both scheduled and surprise inspections by the Quality Assurance staff during different aspects of the manufacturing process help to ensure specific quality, strength and purity for both the raw materials and our finished natural health care supplements.

Additionally, we use only those key materials that are of the highest quality and that pass our strict laboratory inspection. All raw materials are tested for purity prior to production. Quality control scientists have the authority during any stage of production to refuse any product that does not adhere to our strict quality standards. All steps during the manufacturing process are documented and reviewed by quality control specialists; Bio Life Bioengineering's manufacturing equipment is always properly maintained and cleaned.

(A) Business Development.

We are using this Micron Pulverizing technology focusing on breaking the walls of biotic cells; we use this technology to produce Chinese herbs and health food products. Our technology can produce the biological powders of diameter D50=12µm, with 95% of the cells broken, and the minimum diameter of the powder can be just 1µm. In the pulverizing procession of the non-biological materials, the minimum diameter of the powder can be 1-0.1µm, with 10-20% reaching nanometer grade. This will greatly improve their effectiveness and efficiency. Years of innovation and development of know-how have dramatically increased the therapeutic effectiveness and reduced the side-effects of many candidate formulas and herbal preparations for various diseases.

Every product manufactured for BioLife Remedies™ is done so in an internationally approved facility under "Good Manufacturing Practices" (GMP) guidelines. These guidelines assure you that every single tablet sold by BioLife Remedies™ is of the uppermost quality and purest form. At BioLife Remedies your health comes first.

1. The form of organization of the issuer.

The Company is a Nevada corporation.

2. The year that the issuer (or any predecessor) was organized.

The issuer was organized by the filing of the Articles of Incorporation with the Secretary of State Nevada on April 12, 2004. The Company changed its name to BioLife Remedies Inc. through the filing of merger documents with the state of Nevada on January 18, 2007.

3. Issuer's fiscal year end date.

The fiscal year end is December 31.

4. Whether the issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceeding;

The Company and/or any predecessor has not and is not in the process of filing bankruptcy, receivership or any similar proceeding.

5. Any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business;

The Company has not made any material reclassifications, mergers, or consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business.

6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments.

The Company has not had any default of the terms of any note, loan, lease, or other indebtedness or other financing arrangement requiring the issuer to make payments;

7. Any change of control:

No change of control has occurred even though the Issuer has changed its name.

8. Any increase of 10% or more of the same class of outstanding equity securities;

Not applicable.

9. Describe any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization.

The Company consolidated its common stock on the basis of one share for every 250 shares. The consolidation was effective January 19, 2007.

10. Any delisting of the issuer's securities by any securities exchange or NASDAQ.

The Corporation's securities have not been de-listed and are not in the process of being de-listed by the Securities and Exchange Commission or the NASD.

11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.

There are no current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations.

(B) Business of Issuer.

BIOLIFE REMEDIES, INC. (BLRS) combines Traditional Chinese Medicine (TCM), Western academic research and development practices with the newest scientific technology to produce effective medical and health-care products to combat serious diseases. TCM is a natural medical framework developed 3000 years ago in China and over the centuries countless medical formulas have been developed to treat the most common diseases known to afflict man.

For generations the BioLife Group has engaged in TCM as a profession developing 108 master medical formulas. In the Nineties under the leadership of Mr. Jack Guo, BLRS was formed by a group of rhizotomists, herbologists, pharmacists, and TCM practitioners to develop effective natural herbal supplements based on BLRS's master formulas. Over the years 11 products were successfully developed by BFLR to treat various diseases including; diabetes, prostatitis, osteoporosis, cerebrovascular disease, cardiac vascular disease, hypertension, menopausal syndrome, male sexual disorder, female sexual disorder, and intelligence development in children.

Presently the company is concentrating on Natural Supplements to combat the world's most expensive and debilitating disease—DIABETES. Zutro™, Betatrol™, Dia-Kids™ and Di-Agra™ address a well-defined and unanswered need in diabetic medication: a natural medical product that not only treats Diabetes but its many complications.

1. The Issuer's primary and secondary SIC codes.

The Primary SIC code for the Company is 7361, employment services and there is currently no SIC code that fits the secondary SIC code for the Company.

2. If the issuer has never conducted operations, is in the development stage, or is currently conducting operations.

The Company is in the development stage.

3. State the name of any parent, subsidiary or affiliated company.

The Company has no parent, subsidiary or affiliated companies.

4. The effect of existing or probable governmental regulations on the business;

The Company does not foresee any substantial changes that could adversely affect the business of the Company at this time.

5. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;

The Company has spent a great deal of time and preparation on the research and development of the Company and it is hard to put a number on it at this time. The Company can assure the customer that they will not directly or indirectly be affected.

There has been no third party research to date that has required the to pay for the services of a third party. No funds have been expended on research and development. The Company estimates that it has spent approximately 2000 hours on its research and due diligence over the course of the past year.

6. Costs and effects of compliance with environmental laws (federal, state and local);

The Company is not producing any products that are hazardous to the environment and does not foresee any changes that could adversely affect the environment. All products and services are environmentally friendly.

7. Number of total employees and number of full time employees.

The Company has two employees, of which all are full time employees.

(C) Investment Policies.

1. Investments in real estate or interest in real estate.

The Company does not intend to invest in any real estate properties at this time.

2. Investments in real estate mortgages.

The Company does not intend to invest in any type of real estate mortgages.

3. Securities of or interests in persons primarily engaged in real estate activities.

The Company does not intend to invest in any persons primarily engaged in real estate activities.

Item (ix): The nature of products or services offered.

1. Principal products or services, and their markets.

All of our raw materials must pass strict quality controls before they are consumed. All BioLife Group supplements are manufactured using Good Manufacturing Practices (GMP Standards). In addition, both scheduled and surprise inspections by the Quality Assurance staff during different aspects of the manufacturing process help to ensure specific quality, strength and purity for both the raw materials and our finished natural health care supplements.

Additionally, we use only those key materials that are of the highest quality and that pass our strict laboratory inspection. All raw materials are tested for purity prior to production. Quality control scientists have the authority during any stage of production to refuse any product that does not adhere to our strict quality standards. All steps during the manufacturing process are documented and reviewed by quality control specialists; Bio Life Bioengineering's manufacturing equipment is always properly maintained and cleaned.

2. Distribution methods of the products or services.

The Company's primary distribution at this point is through its website located at www.blfrproducts.com

3. Status of any publicly announced new product or services.

Please see publicly disclosed news releases and the company website for status of new products.

4. Competitive business conditions, the issuer's competitive position in the industry, and methods of competition.

None currently identified.

5. Sources and availability of raw materials and the names of principal suppliers.

All of our raw materials must pass strict quality controls before they are consumed. All BioLife Group supplements are manufactured using Good Manufacturing Practices (GMP Standards). In addition, both scheduled and surprise inspections by the Quality Assurance staff during different aspects of the manufacturing process help to ensure specific quality, strength and purity for both the raw materials and our finished natural health care supplements.

Additionally, we use only those key materials that are of the highest quality and that pass our strict laboratory inspection. All raw materials are tested for purity prior to production. Quality control scientists have the authority during any stage of production to refuse any product that does not adhere to our strict quality standards. All steps during the manufacturing process are documented and reviewed by quality control specialists; Bio Life Bioengineering's manufacturing equipment is always properly maintained and cleaned.

6. Dependence on one or a few major customers.

The Company depends on numerous customers in the industry. The Company is not dependant on one major customer for the endurance of the Company and looks forward to the future business that is to be provided.

management and business development for BioLife Group, including marketing strategies, distribution channels, advertising, promotion and sales force.

SU ZHIHONG DIRECTOR

Mr. Su is a professor and a doctor specializing in Tumor treatment and Endocrinology. Graduated from Tianjin Medical Institute, Mr. Su engaged in clinical practice in Tianjin second central hospital. In the 70's, Mr. Su studied TCM for more than 10 years following renowned TCM professor Wang Shifu of Tianjin Chinese Medicine Institute. Since then, Mr. Su has taken combined applications of TCM and Western Medicine as an academic path, and engaged in the research of combined applications of TCM and Western Medicine for first-aid of critical and serious diseases. Mr. Su has conducted research on the immunoreaction effect of Macrophage, treatment of outburst modis during the resting period of the malignant tumor, the qualitative difference of type I and Type II diabetic pathology and Physiology, and the theory and clinical research of the decay of pancreatic cell. Mr. Su is currently serving as the Secretary General of the Traditional Chinese Medicine in Combination of Western Medicine First-aid Institute of China.

B. Directors.

Please see above

C. General Partner

This does not apply to the Company.

D. Investment Banker

This does not apply to the Company.

E. Promoter

None at this moment.

F. Control Persons

The Board of Directors of the Company is the only entity considered to be control persons of the Company.

G. Counsel.

None at this moment.

H. Accountant or Auditor.

None at this moment.

I. Public relations.

None at this moment.

J. Any other advisor (s) that assisted, advised, prepared or provided information with respect to this disclosure documentation.

None.

Indicate whether any of the above named individuals in the last 5 years have been:

1. Convicted of any criminal proceedings or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None.

2. Has not had an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities or banking activities

None.

3. Has not had a finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated.

None.

4. Has not had an entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

None.

Shareholders holding more than five percent (5%) of the common stock of the Company's issued and outstanding shares.

Bio Life Bioengineering (China) Inc.

JACK GUO

Item (xii): The issuers' most recent balance sheet and profit and loss and retained earnings statements.

See attached financial statements.

Item (xiii): Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence.

See attached financial information.

Item (xvi): Whether any quotation is being submitted or published directly or indirectly on behalf of the issuer, or any director, officer or any person, directly or indirectly the beneficial owner of more than 10 percent of the outstanding units or shares of any equity security of the issuer, or at the request of any promoter for the issuer, and, if so, the name of such person,

and the basis for any exemption under the federal securities laws for any sales of such securities on behalf of such person.

The Issuer has no knowledge of any broker-dealer(s) or associated persons who is/are submitting quotations with respect to the Issuer's Common Stock, who may be associated, directly or indirectly, on behalf of the Issuer or on behalf of a director, officer or beneficial owners of more than ten (10) percent of the Common Stock that is issued and outstanding.

INFORMATION AND DISCLOSURE STATEMENT

ALL INFORMATION FURNISHED HEREIN HAS BEEN PREPARED FROM THE BOOKS AND RECORDS OBTAINED FROM THE COMPANY IN ACCORDANCE WITH RULE 15C2-11(A)(5) PROMULGATED UNDER THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED.

NO DEALER, SALESMAN OR ANY OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS NOT CONTAINED HEREIN IN CONNECTION WITH THE COMPANY. ANY REPRESENTATIONS NOT CONTAINED HEREIN MUST NOT BE RELIED UPON AS HAVING BEEN MADE OR AUTHORIZED BY THE COMPANY.

The undersigned hereby certifies that the information herein is true, complete, presented fairly, and correct to the best of their knowledge and belief.

BIOLIFE REMEDIES INC.

Certified by: /s/ JACK GUO
Jack Guo, President